Novartis’ Kisqali increases OS in HR+/HER2- advanced breast cancer in phase 3 trial

This article was originally published here

The Kisqali combination therapy, which was evaluated in both pre- and perimenopausal women in the late-stage trial called MONALEESA-7, delivered statistically significant overall survival (OS) results in comparison

The post Novartis’ Kisqali increases OS in HR+/HER2- advanced breast cancer in phase 3 trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply